Health Care Equipment

Sight Sciences

Sight Sciences released FY2026 Q1 earnings on May 6 After-Market EST, actual revenue USD 19.7 M (forecast USD 18.55 M), actual EPS USD -0.2406 (forecast USD -0.1744)

Sight Sciences to Release FY2026 Q1 Earnings on May 6 After-Market EST, Forecast Revenue USD 18.55 M, EPS USD -0.1744

Sight Sciences released FY2025 Q4 earnings on March 4 After-Market EST, actual revenue USD 20.39 M (forecast USD 20.34 M), actual EPS USD -0.0784 (forecast USD -0.146)

Sight Sciences released FY2025 Annual Earnings on March 4 After-Market EST, actual revenue USD 77.36 M (forecast USD 77.33 M), actual EPS USD -0.7368 (forecast USD -0.7181)

Sight Sciences to Release FY2025 Q4 Earnings on March 4, 2026, After-Market EST; Forecast Revenue USD 20.35 M, EPS USD -0.1594

Sight Sciences released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 19.91 M (forecast USD 17.74 M), actual EPS USD -0.16 (forecast USD -0.2638)

Sight Sciences released FY2025 9 Months Earnings on November 6 After-Market EST, actual revenue USD 56.98 M, actual EPS USD -0.6623

Sight Sciences Inc Expects Tariffs to Raise 2025 Cost for Glaucoma Surgery Division by $1-1.5M

Lake Street Analyst Reiterates Buy Rating on Sight Sciences

Takkinen Covers Healthcare Industry Stocks

Sight Sciences to Release FY2025 Q3 Earnings on November 6 After-Market EST, Forecast Revenue USD 17.74 M, EPS USD -0.2638

Antalffy and Lake Street Reiterate Buy Rating on Sight Sciences Stock

Takkinen Reiterates Hold Rating on Sight Sciences

Takkinen Analyzing Healthcare Industry Stocks

Sight Sciences released FY2025 Q2 earnings on August 7 After-Market (EST), actual revenue USD 19.56 M (forecast USD 18.18 M), actual EPS USD -0.2304 (forecast USD -0.2711)

Sight Sciences released FY2025 Semi-Annual earnings on August 7 After-Market (EST), actual revenue USD 37.07 M, actual EPS USD -0.5061

Sight Sciences to Release FY2025 Q2 Earnings on August 7 After-Market EST, Forecast Revenue USD 18.18 M, EPS USD -0.2711

Piper Sandler Maintains Neutral Rating on Sight Sciences with Target Price Raised to $4.00

Staffan Encrantz Acquires Shares of Sight Sciences Inc.

Staffan Encrantz Increases Holdings in Sight Sciences

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

SGHT

SMLF

Sight Sciences, Inc. (NASDAQ:SGHT) has received a consensus recommendation of 'Hold' from nine analysts. The average target price is $8.31, with one sell, three hold, and five buy ratings. Recent insider sales include Jeremy B. Hayden selling 13,761 shares and CTO David Badawi selling 8,168 shares. The stock is currently valued at $5.20, up 6.1%, with a market cap of $282.93 million. The company reported a quarterly EPS of ($0.24), missing estimates.

Market Beat

ISHRS Russ 2000 Growth

iShares US SmallCap Equity Factor

SPDR S&P Health Equip

iShares US Medical Devices

UBS Group AG

Citigroup

Manulife Financial

MANULIFE-S

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Sight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Recommendation of "Hold" from Analysts

Sight Sciences shares are trading higher. The company reported Q1 financial results and raised its FY26 sales guidance with its midpoint above estimates.

benzinga_article

Sight Sciences (NASDAQ:SGHT) reported quarterly earnings with an EPS of ($0.24), missing estimates of ($0.19). Revenue was $19.70 million, exceeding the $18.47 million estimate. The company has a negative return on equity of 55.72% and a negative net margin of 49.67%. The stock traded down 0.7% to $4.30. Recent insider sales included CTO David Badawi selling 8,168 shares and insider Jeremy B. Hayden selling 13,761 shares. Institutional investors own 55.51% of the company, and analysts have mixed ratings with a consensus hold rating and an average price target of $8.31.

Invesco

Cantor Equity Partners

Cantor Equity Partners IV

Stifel Financial

Millennium

Millennium Services Group Ltd.

Cantor Equity Partners VI

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Sight Sciences (NASDAQ:SGHT) Announces Quarterly Earnings Results

Earnings Watch

Sight Sciences | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 19.7 M

Sight Sciences (SGHT) has won a patent infringement lawsuit against Alcon, with the U.S. District Court awarding $55.4 million in damages and a 10% ongoing royalty on Hydrus revenue. However, the ruling is subject to appeal, and damages will not be received until appeals are resolved. Analysts rate SGHT stock as a Hold with a $4.35 price target, citing weak financial performance and a bearish technical setup, despite some positive trends in profitability and growth guidance. Sight Sciences focuses on ophthalmology technologies for eye disease treatment.

Tip Ranks

Alcon

Sight Sciences Wins Patent Judgment, Secures Ongoing Royalties

Sight Sciences has secured a final judgment of $55.4 million and a 10% ongoing royalty from Alcon for willful patent infringement. The judgment confirms the validity of three patents and includes $34 million in past damages, $14.7 million in supplemental damages, and $6.8 million in interest. The ongoing royalty applies to Hydrus sales until the last patent expires. However, the award is subject to appeal by Alcon, and no funds will be received until the appeal process is complete.

TradingView

Sight Sciences wins $55.4M patent judgment, 10% ongoing royalty on Hydrus sales

Sight Sciences, Inc. (Nasdaq: SGHT) has released its annual Sustainability Report, detailing its environmental, social, and governance (ESG) initiatives from 2023 to 2025. The report highlights a >20% reduction in emissions and the company's commitment to transparency and accountability. Key initiatives include community support, diversity, and employee well-being. As of December 31, 2025, 56% of the workforce are women. The report underscores Sight Sciences' mission to enhance eyecare through innovative technologies while maintaining strong ESG practices.

StockTitan

Sight Sciences Announces the Release of its Sustainability Report | SGHT Stock News

Sight Sciences(SGHT.US)